BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference

     BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013
                            Healthcare Conference

PR Newswire

LYNBROOK, N.Y., Sept. 19, 2013

LYNBROOK, N.Y., Sept.19, 2013 /PRNewswire/ --BioSpecifics Technologies Corp.
(NASDAQ: BSTC), a biopharmaceutical company developing first-in-class
collagenase-based products marketed as XIAFLEX^® in the U.S and XIAPEX^® in
the EU, today announced that BioSpecifics' President, Tom Wegman, will present
a corporate overview at the Aegis Capital 2013 Healthcare Conference.

The presentation will take place on Thursday, September 26, 2013 at 4:00 p.m.
EDT (1:00 p.m. PDT) at the Encore at Wynn hotel in Las Vegas, NV. This event
will not be webcast.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for twelve clinical indications to date.
Injectable collagenase is currently marketed as XIAFLEX^® (collagenase
clostridium histolyticum (CCH)) in the U.S. for the treatment of adult
Dupuytren's contracture patients with a palpable cord in the palm by
BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed
in Europe and approved in Canada. Swedish Orphan Biovitrum AB has marketing
rights for XIAPEX^® (the EU tradename for CCH) for the treatment of
Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African
countries. Asahi Kasei Pharma Corporation has development and
commercialization rights for XIAFLEX for the treatment of Dupuytren's
contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals Ltd.
has development and commercialization rights for XIAFLEX for these two
indications in Canada, Mexico, Brazil and Australia. CCH is in clinical
development for the treatment of several additional promising indications. The
PDUFA date for XIAFLEX for Peyronie's disease is December 6, 2013.Auxilium is
also testing CCH for frozen shoulder syndrome and cellulite. Auxilium expects
to initiate a Phase II trial of CCH for cellulite in the third quarter of this
year and next stage trials of CCH for frozen shoulder syndrome in the fourth
quarter of 2013. BioSpecifics is currently managing the development of CCH for
the treatment of human and canine lipomas, both of which are in Phase II
trials. BioSpecifics expects top-line data from these trials in the second
half of the year. For more information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.

Website: http://www.biospecifics.com
Contact: BioSpecifics Technologies Corp., Thomas L. Wegman, President, (516)
593-7000, thomas_wegman@biospecifics.com
 
Press spacebar to pause and continue. Press esc to stop.